VivoSeq
Oncology

Pancreatic Carcinoma

41

Pipeline Programs↗

6

Active Trials↗

23

Companies Involved↗

Pancreatic Carcinoma is a moderately active landscape with 41 programs across 23 companies. The most active players are Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd., Sorrento Therapeutics, Inc.. 1 therapy is approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

0/100

Mech. Concentration

18/100

Completion Rate

81/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

2 programs

Phase 1Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

2 programs

Phase 1S

Sorrento Therapeutics, Inc.

1 program

Phase 1Bayer logo

Bayer

1 program

Phase 1Amgen logo

Amgen

1 program

Phase 1P

Phanes Therapeutics

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

35 of 42 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody410%Cell therapy25%RNA therapy12%

Small molecule leads; the ring shows all 42 classified programs, each share of the total. Modality classified for 96% of 49 pipeline programs.

Analysis

Trial Status

31

clinical trials

Completed17 · 55%
Unknown status4 · 13%
Terminated3 · 10%
Recruiting3 · 10%
Active, not recruiting2 · 6%
Withdrawn1 · 3%
Other1 · 3%

Clinical Trials

Trial Activity

31 trials

Implantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma
Recruiting·—·N/A·NCT05869474·206 enrolled
Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma
Recruiting·EEIR Biotherapies s.r.l.·Phase 1/2·NCT06861452·9 enrolled
Assessing the Role of Intraoperative Indocyanine Green Perfusion of the Transected Pancreas in Predicting Postoperative Pancreatic Leaks
Recruiting·OOHSU Knight Cancer Institute·N/A·NCT06084013·55 enrolled
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
Active, not recruiting·IInstitut de Cancérologie de Lorraine·Phase 2·NCT02676349·130 enrolled
GENetic Education Risk Assessment and TEsting Study (GENERATE)
Active, not recruiting·DDana-Farber Cancer Institute·Preclinical·NCT03762590·1,000 enrolled
Canagliflozin With Gemcitabine in Pancreatic Carcinoma
Not yet recruiting·ZZhang Xiaofeng,MD·N/A·NCT05903703·20 enrolled
Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:
Completed·—·Phase 2·NCT03861702·28 enrolled
Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets
Completed·CCentro Nacional de Investigaciones Oncologicas CARLOS III·Phase 2·NCT01454180·31 enrolled
Phase I-II to Evaluate Efficacy/Safety of Sorafenib+Gemcitabine+Radiotherapy in Locally Advanced Pancreatic Carcinoma
Completed·GGrupo Espanol Multidisciplinario del Cancer Digestivo·Phase 1·NCT00789763·12 enrolled
A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma
Completed·UUNICANCER·Phase 3·NCT02539537·171 enrolled
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Completed·UUniversity of Liverpool·Phase 2·NCT01601808·142 enrolled
An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma
Completed·CCancer Advances Inc.·Phase 2·NCT02098291·34 enrolled
Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma
Completed·EERYtech Pharma·Phase 2·NCT02195180·141 enrolled
Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy
Completed·UUniversity of Erlangen-Nürnberg Medical School·Phase 3·NCT01827553·830 enrolled
Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
Completed·—·Phase 1·NCT02588443·19 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)